JPRN-UMIN000044991已完成未知
Reopenable Clip Over the line Method (ROLM) for mucosal defect after gastric endoscopic submucosal dissection: a prospective study - Reopenable Clip Over the line Method (ROLM) for mucosal defect after gastric endoscopic submucosal dissection: a prospective study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Cases with severe complications are excluded. Post ESD mucosal defects bordering the pylorus or cardia. Mucosal defect after ESD is larger than half circumference of the gastric lumen.
研究者
相似试验
已完成
1 期
Clip on Clip Closure Method (CCCM) for mucosal defect after colorectal endoscopic submucosal dissection: a prospective studyEarly colorectal cancer and colorectal adenomaJPRN-UMIN000031420Ise Red Cross Hospital30
已完成
1 期
Clip on Clip Closure Method (CCCM) for mucosal defect after gastric endoscopic submucosal dissection: a prospective studyearly gastric cancer and gastric adenomaJPRN-UMIN000031425Ise Red Cross Hospital30
进行中（未招募）
1 期
A rollover study for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib alone or in combination with other agentsEUCTR2016-000293-37-FRovartis Pharma Services AG40
进行中（未招募）
1 期
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatmentsDifferent types of advanced cancerMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028997Term: Neoplasm malignant Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-508841-42-00ovartis Pharma AG119
招募中
2 期
An open-label, multi-center rollover protocol for patients
who have participated in a Novartis-sponsored ribociclib
(LEE011) study and are continuing to benefit from
ribociclib as single agent or in combination with other
investigational treatments2024-511125-61-00Novartis Pharma AG1